Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;18(1):29-37.
doi: 10.3201/eid1801.110850.

High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010

Affiliations

High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010

Elisabeth Sanchez-Padilla et al. Emerg Infect Dis. 2012 Jan.

Abstract

In Africa, although emergence of multidrug-resistant (MDR) tuberculosis (TB) represents a serious threat in countries severely affected by the HIV epidemic, most countries lack drug-resistant TB data. This finding was particularly true in the Kingdom of Swaziland, which has the world's highest HIV and TB prevalences. Therefore, we conducted a national survey in 2009-2010 to measure prevalence of drug-resistant TB. Of 988 patients screened, 420 new case-patients and 420 previously treated case-patients met the study criteria. Among culture-positive patients, 15.3% new case-patients and 49.5% previously treated case-patients harbored drug-resistant strains. MDR TB prevalence was 7.7% and 33.8% among new case-patients and previously treated case-patients, respectively. HIV infection and past TB treatment were independently associated with MDR TB. The findings assert the need for wide-scale intervention in resource-limited contexts such as Swaziland, where diagnostic and treatment facilities and health personnel are lacking.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tuberculosis diagnosis facilities (red diamonds), Swaziland.
Figure 2
Figure 2
Study profile, national drug-resistant tuberculosis (TB) survey, Swaziland, 2009–2010. A) New patients; B) previously treated patients. NRL, National Reference Laboratory; MTB, Mycobacterium tuberculosis; MOTT, mycobacteria other than tuberculosis. *MTB + MOTT. †1 MTB + MOTT, 2 MTB + other bacteria (nonmycobacteria).

Similar articles

Cited by

References

    1. World Health Organization. Global tuberculosis control. Geneva: The Organization; 2010.
    1. World Health Organization. The stop TB strategy: building on and enhancing DOTS to meet the TB related millennium development goals. Geneva: The Organization; 2006.
    1. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059–64. 10.1016/S0140-6736(02)08904-3 - DOI - PubMed
    1. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 4th edition. Geneva: The Organization; 2009.
    1. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO progress report 2011. Geneva: The Organization; 2011.

Publication types

LinkOut - more resources